Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406536 · ClinicalTrials.gov registry record · Phase 2
Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI
A Phase 2 study of Cystic Fibrosis and Pancreatic Insufficiency, sponsored by Avanti Polar Lipids.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT00406536 is a Phase 2 study of Cystic Fibrosis and Pancreatic Insufficiency that has completed, run by Avanti Polar Lipids. The registered enrollment target is 110 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00406536, a Phase 2 study of Cystic Fibrosis and Pancreatic Insufficiency, has completed, sponsored by Avanti Polar Lipids.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this phase II research study is to evaluate the effectiveness of the next generation LYM-X-SORB™ in improving the essential fatty acid (EFA) and choline status for children and adolescents with Cystic Fibrosis (CF) and pancreatic insufficiency (PI).
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Lym-X-Sorb powder
- DIETARY_SUPPLEMENT Placebo powder
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia (CHOP) - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2007-01 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00406536
The ClinicalTrials.gov registry entry for NCT00406536 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (39% lower). The listed sponsor is Avanti Polar Lipids, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Lym-X-Sorb powder is the first listed.
NCT00406536 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00406536 about?
NCT00406536 is a clinical study titled "Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI". The purpose of this phase II research study is to evaluate the effectiveness of the next generation LYM-X-SORB™ in improving the essential fatty acid (EFA) and choline status for children and adolescents with Cystic Fibrosis (CF) and pancreatic insufficiency (PI).
What is the current status of trial NCT00406536?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2007-01. Estimated completion is 2012-06.
What conditions does trial NCT00406536 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Pancreatic Insufficiency.
What interventions are being tested in trial NCT00406536?
The interventions under investigation include: Lym-X-Sorb powder (DIETARY_SUPPLEMENT), Placebo powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00406536?
This trial is sponsored by Avanti Polar Lipids, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00406536 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
RECRUITING · Phase 2
-
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
RECRUITING · Phase 2
-
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
RECRUITING · Phase 2
-
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.